QUOTE AND NEWS
FierceBiotech  Feb 25  Comment 
Japanese giant Takeda Pharmaceutical is planning to finally return to growth next year, counting on its late-stage medicines to the lead charge.
FiercePharma  Feb 25  Comment 
Takeda's revenues and profits will be down for the second year running. But COO Christophe Weber is promising better things to come. With a reorganization in place and some new drugs in the market and the pipeline, he said investors can expect...
FiercePharma  Feb 24  Comment 
Takeda's CEO-in-waiting, Christophe Weber, has included emerging markets, along with oncology and gastrointestinal medicines, as one of three areas of focus. He recently said he is ready to do some deals to capitalize on those areas, and now he...
FierceBiotech  Feb 17  Comment 
Three years after Takeda decided to double down on motesanib for non-small cell lung cancer, in-licensing full rights to the drug from Amgen following their big Phase III failure in 2011, the company has once again come up empty-handed in a major...
FierceBiotech  Feb 10  Comment 
Takeda's top oncology prospect met its main goal in a Phase III trial, the Japanese drugmaker said, paving the path to an FDA submission for a drug the company hopes can succeed its blockbuster Velcade.
FiercePharma  Jan 22  Comment 
Another purported Sanofi CEO candidate has publicly knocked himself off the list. Takeda chief operating officer and CEO-in-waiting Christophe Weber says he's not interested in the job. That makes two top pharma execs who've rebuffed the French...
FiercePharma  Jan 21  Comment 
Step one for incoming Takeda CEO Christophe Weber: Reorganize. Step two? Scout deals, he said Wednesday.
FierceBiotech  Jan 20  Comment 
Johnson & Johnson has opened the doors on its Takeda-partnered biotech incubator in Israel, enrolling its first class of startups and advancing its global plan to accelerate R&D through external innovation.
FierceBiotech  Jan 12  Comment 
Oncology biotech Mersana Therapeutics has expanded its relationship with Takeda, forging an agreement to develop targeted cancer drugs with as much as $300 million on the line.




 
TOP CONTRIBUTORS

No more s***. All posts of this qaultiy from now on

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki